Free Trial
OTCMKTS:KNBWY

Kirin 2/13/2026 Earnings Report

Kirin logo
$16.23 +0.18 (+1.12%)
As of 05/7/2026 03:59 PM Eastern

Kirin EPS Results

Actual EPS
$0.36
Consensus EPS
$0.30
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Kirin Revenue Results

Actual Revenue
$4.44 billion
Expected Revenue
$4.22 billion
Beat/Miss
Beat by +$214.36 million
YoY Revenue Growth
N/A

Kirin Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Kirin's next earnings date is estimated for Tuesday, May 12, 2026, based on past reporting schedules.

Conference Call Resources

Kirin Earnings Headlines

Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
KNBWY Kirin Holdings Company, Limited - Seeking Alpha
Kirin Holdings Co Stock Price History
Kirin Holdings: Q1 Performance Had Mixed Takeaways
See More Kirin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kirin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kirin and other key companies, straight to your email.

About Kirin

Kirin (OTCMKTS:KNBWY) Holdings Company, Limited is a Japan-based global beverage and life sciences group best known for its flagship beer brand. The company’s core operations encompass the brewing and distribution of beer and spirits, the production of soft drinks and other non-alcoholic beverages, and a growing pharmaceuticals and biotech segment. Kirin’s beverage portfolio ranges from mainstream lagers and craft-inspired brews to juices, teas, and carbonated soft drinks sold under various regional labels.

Rooted in the founding of Kirin Brewery Company in 1888, the group restructured into a pure holding company in 2007 to foster greater strategic flexibility. Over more than a century of expansion, Kirin has grown beyond Japan to establish a presence across Asia, Oceania, the Americas and Europe. Notable milestones include its majority stake in Australia’s Lion Nathan, partnerships with Chinese soft-drink bottlers, and the 2019 consolidation of its global pharmaceutical operations under Kyowa Kirin Co., Ltd., focusing on oncology, immunology and nephrology therapies.

The company is led by President and CEO Yoshinori Isozaki, who took the helm in April 2021. Under his stewardship, Kirin has emphasized sustainable practices—from water stewardship at its breweries to circular packaging initiatives—and continues to explore growth opportunities in health science through R&D investments. With a diversified business model spanning beverages and life sciences, Kirin Holdings leverages its century-long heritage to pursue innovation and resilience in global markets.

View Kirin Profile